Biogen to Acquire Reata for $7.3 Billion
- Posted by ISPE Boston
- On August 10, 2023
Biogen has agreed to acquire Plano, Texas-based Reata Pharmaceuticals for $172.50 per share in cash, reflecting an enterprise value of approximately $7.3 billion. Reata has made significant advancements developing therapeutics that regulate cellular metabolism and inflammation in serious neurologic diseases. Reata’s FDA-approved Skyclarys (omaveloxolone) is the first and only approved treatment in the U.S. for the […]
Read More